News Category Global Banking & Finance Reviews
CHSI Technologies Continues Delivering on Business Momentum and Product Innovation with Record Growth Numbers in 2020
CHSI Technologies Continues Delivering on Business Momentum and Product Innovation with Record Growth Numbers in 2020 CHSI Technologies (CHSI or the Company), the market-leading SaaS InsureTech firm for policy and claims lifecycle management, billing, decision support and analytics announced record financial results and exponential sales growth in 2020. Post CHSIs majority recapitalization in Q4 2019 by Bow River Capitals SaaS Growth Equity Fund, CHSI executed on its strategic vision and operating plan; highlighted by releasing modern SaaS Claims and Portal modules, aggressively scaling each business unit, and re-engineering the Companys go-to-market engine.
Laois GPs can send patients to private hospitals for x-rays and range of other tests under a new deal
Reporter: );
);
Family doctors in Laois and other counties will soon be able to bypass local hospitals and refer patients for x-rays, MRI and CT scans and other diagnostics to private providers, under a deal announced by the Minister for Health, Stephen Donnelly.
Under deal the HSE is to make available to GPs increased direct access to diagnostic services from this week. A statement said that the initiative would give GPs across the country the ability to access an additional 94,000 diagnostic procedures, such as X-Rays, CT scans, MRIs, and DEXA .
PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals
News provided by
Share this article
Share this article
SANDUSKY, OH, Jan. 14, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today published a management outlook for 2021 on the company s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:
PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook
PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.
PAO Group, Inc.: PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook
Sandusky, Ohio (Newsfile Corp. - January 14, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today published a management outlook for 2021 on the company s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:
PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook
PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.
PAO Group, Inc.: PAOG Develops CBD Nutraceutical for $12.7 Billion from Patented Extract Process
Sandusky, Ohio (Newsfile Corp. - December 18, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020.
Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
PAOG, through its engagement with PRCCI, expects to rapidly produce its CBD COPD Nutraceutical product and establish sales. Grand View Research forecasts the CBD Nutraceutical marketplace reaching a value of $12.7 billion by 2025.